Global Human Interleukin IL Market Size, Share, and Trends Analysis Report, By Type (IL-2, IL-4, IL-5, IL-6, and Others) and By Application (Autoimmune Diseases, Tumors, Inflammatory Diseases, and Others), Forecast (2022-2028)

The global Human Interleukin IL market is anticipated to grow at a considerable CAGR of 16.7% during the forecast period (2022-2028). Human interleukin IL is a group of cytokines, a protein with a single molecule expressed by the white blood cells. Human interleukin IL plays a major role in the function and application of several conditions including autoimmune diseases, tumors, and others. The major factor attributing to the growth of the global human interleukin IL market includes the increasing application of human interleukin in the rising prevalence of autoimmune diseases across the globe. According to the National Stem Cell Foundation (NSCF), autoimmune diseases are considered the third most common cause of chronic illness having more than 80 different types of autoimmune diseases. Around 4% of the global population is estimated to be affected by any one type of autoimmune disease. Some common types of autoimmune diseases include type-1 diabetes, lupus, multiple sclerosis, psoriasis, and scleroderma. The American Autoimmune Related Disease Association (AARDA) estimated that around 50 million people are living with any one type of autoimmune disease in the US alone which creates economical burden of $86 billion.

In addition, the application of human interleukin IL in the management of tumors, generally known as cancer is also increasing. According to the World Cancer Research Fund (WCRF), around 18.1 million cancer cases were diagnosed across the globe in 2020. Among these, around 9.3 million cases were of men, and around 8.8 million cases were of women. Furthermore, the application of human interleukin IL in several inflammatory diseases including chronic inflammation is also contributing to the growth of the market. According to the report published by the National Center for Biotechnology Information (NCBI) in September 2021, 3 in every 5 mortality that occurred in the US is due to chronic inflammation. The report also describes that the prevalence of chronic inflammation is estimated to increase constantly for the next 3 decades. Thus, propelling the growth of the global human interleukin IL market.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape– AbbVie Inc., F. Hoffmann-La Roche Ltd., Bristol Myers Squibb (BMS), Alkermes plc, and APT Therapeutics, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Human Interleukin IL  Market Report by Segment

By Type

• IL-2
• IL-4
• IL-5
• IL-6
• Others

By Application

• Autoimmune Diseases
• Inflammatory Diseases
• Tumors
• Others

Global Human Interleukin IL  Market Report by Region

North America

• The United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa